Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEIII) | recruiting | Phase 3 | 600 | LeonaBioINDUSTRY | 17 | Jun 22, 2026 | clinicaltrials |
| NCT07084519 | Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction | recruiting | Phase 3 | 506 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER |
| 1 |
| Jun 22, 2026 |
| clinicaltrials |
| NCT06960707 | Two Versus One Week Breast Radiotherapy (RT)(PRATO) | recruiting | Phase 3 | 400 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05950945 | Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | recruiting | Phase 3 | 250 | Daiichi SankyoINDUSTRY | 10 | Jun 12, 2026 | clinicaltrials |
| NCT06763328 | Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | recruiting | Phase 3 | 80 | City of Hope Medical CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07518173 | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 596 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07615751 | Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer | recruiting | Phase 3 | 502 | Fudan UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07237256 | Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib(NoLEEta) | recruiting | Phase 3 | 3,902 | UNICANCEROTHER | 5 | May 26, 2026 | clinicaltrials |
| NCT07349069 | A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer | recruiting | Phase 3 | 5,500 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | recruiting | Phase 3 | 1,180 | Celcuity IncINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT07357298 | Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer | recruiting | Phase 3 | 156 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06081959 | Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | recruiting | Phase 3 | 376 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06279364 | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 524 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07071337 | A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy | recruiting | Phase 3 | 430 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07400523 | Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy | recruiting | Phase 3 | 446 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04852887 | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)(DEBRA) | recruiting | Phase 3 | 1,670 | NRG OncologyOTHER | 4 | Apr 23, 2026 | clinicaltrials |
| NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | recruiting | Phase 3 | 246 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06195709 | ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients(ECLECTIC) | recruiting | Phase 3 | 300 | Institut CurieOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07533123 | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care | recruiting | Phase 3 | 364 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | recruiting | Phase 3 | 1,800 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06954961 | A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 3 | 640 | InventisBio Co., LtdINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07043725 | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | recruiting | Phase 3 | 544 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05806060 | Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer(BCTOP-T-M01) | recruiting | Phase 3 | 134 | Fudan UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06767527 | AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 416 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07467330 | Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment | recruiting | Phase 3 | 258 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer | recruiting | Phase 3 | 540 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06135714 | Metastasis-directed Therapy for Oligometastases of Breast Cancer(OLIGAMI) | recruiting | Phase 3 | 340 | Tokyo Medical and Dental UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT05439005 | Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.(OFOBA) | recruiting | Phase 3 | 158 | Institut CurieOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06704945 | No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy(Neo-NAUTILUS) | recruiting | Phase 3 | 464 | Seoul National University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07024173 | A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | recruiting | Phase 3 | 240 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07362914 | Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions(CHORD) | recruiting | Phase 3 | 182 | Fudan UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06830889 | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy | recruiting | Phase 3 | 1,450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05909332 | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | recruiting | Phase 3 | 764 | Fudan UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06957886 | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer | recruiting | Phase 3 | 566 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07019363 | CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) | recruiting | Phase 3 | 1,903 | Fudan UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07350928 | Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status | recruiting | Phase 3 | 394 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04722978 | Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 228 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06781996 | A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer(HOPE) | recruiting | Phase 3 | 180 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06144164 | A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer | recruiting | Phase 3 | 285 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT07166042 | Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies(Med-RT BG) | recruiting | Phase 3 | 34 | University of UtahOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07190443 | Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)(AURA) | recruiting | Phase 3 | 290 | Japanese Foundation for Cancer ResearchOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06079983 | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | recruiting | Phase 3 | 400 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 22, 2026source: clinicaltrials